Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1755 results
February 2023
-
StatementNovartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
-
Media ReleaseNovartis announces the appointment of the Chairman-Designate of Sandoz Board of DirectorsGilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz BoardMr Ghostine to begin role as Sandoz Chairman following the spin-…
-
StatementNovartis releases emergency funding of USD 1 million for people in Turkey and Syria, and launches employee donation and volunteering programs
-
StatementNovartis announces support for people affected by the earthquake in Turkey and Syria
-
Media ReleaseSandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDASubmission supported by comprehensive analytical and clinical data packageDenosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2Sandoz continues to…
-
Story Patient Perspectives
When you think of the word ‘cancer’, what are the first words that spring to mind?Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?
-
Media ReleasePatients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week…
-
Key ReleaseNovartis continues to grow with further core margin expansion and achieves important innovation milestonesAd hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
-
Key ReleaseNovartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovationAnnonce événementielle au sens de l’art. 53 RCExercice entier Chiffre d’affaires net en hausse de +4% (tcc1, -2% USD) et résultat opérationnel core croissant de +8% (tcc, 0% USD) Innovative…
-
Key ReleaseNovartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteineAd-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative Medicines (IM)…
-
Featured NewsNovartis 2022 Financial ResultsNovartis announces the company’s fourth quarter and 2022 full year financial results.